 |
 |
|
1 October 1994 | Volume 121 Issue 7 | Pages 492-501
Objective: To determine if filgrastim (recombinant human methionyl granulocyte colony-stimulating factor) used in addition to standard inpatient antibiotic therapy accelerated recovery from infection associated with chemotherapy-induced neutropenia.
Design: Randomized, double-blind, placebo-controlled trial.
Setting: Hematology and oncology wards of four teaching hospitals.
Patients: 218 patients with cancer who had fever (temperature >38.2 °C) and neutropenia (neutrophil count <1.0 x 109/L) after chemotherapy.
Intervention: Patients were randomly assigned to receive filgrastim (12 µg/kg of body weight per day) (n = 109) or placebo (n = 107) beginning within 12 hours of empiric therapy with tobramycin and piperacillin. Patients received treatment and remained in the study until the neutrophil count was greater than 0.5 x 109/L and until 4 days without fever (temperature <37.5 °C) had elapsed.
Measurements: Days of neutropenia and fever and days in the study (hospitalization); time to resolution of fever and febrile neutropenia; and frequency of the use of alternative antibiotics.
Results: Compared with placebo, filgrastim reduced the median number of days of neutropenia (3.0 compared with 4.0 days of a neutrophil count of <0.5 x 109/L; P = 0.005) and the time to resolution of febrile neutropenia (5.0 compared with 6.0 days; P = 0.01) but not days of fever (3.0 days for both groups). The frequency of the use of alternative antibiotics was similar in the two groups (46% compared with 41%; P = 0.48). The median number of days patients were hospitalized while on study was the same (8.0 days; P = 0.09); however, filgrastim decreased the risk for prolonged hospitalization (>11 days, 4th quartile) by half (relative risk, 2.1 [95% CI, 1.1 to 4.1]; P = 0.02). In exploratory subset analyses, filgrastim appeared to provide the greatest benefit in patients with documented infection and in patients presenting with neutrophil counts of less than 0.1 x 109/L.
Conclusions: Filgrastim treatment used with antibiotics at the onset of febrile neutropenia in patients with cancer who have received chemotherapy accelerated neutrophil recovery and shortened the duration of febrile neutropenia.
Author and Article Information
From the Ludwig Institute for Cancer Research, the Royal Melbourne Hospital, and the Peter MacCallum Cancer Institute, Melbourne, Victoria, Australia; the Austin Hospital, Heidelberg, Australia; Westmead Hospital, New South Wales, Australia; Amgen, Inc., Thousand Oaks, California.
ARTICLE
Filgrastim in Patients with Chemotherapy-induced Febrile Neutropenia: A Double-Blind, Placebo-Controlled Trial
Requests for Reprints: Darryl W. Maher, MB, BS, PhD, Melbourne Tumor Biology Branch, Ludwig Institute for Cancer Research, P.O. The Royal Melbourne Hospital, Victoria, Australia 3050.
Acknowledgments: The authors thank A. Burgess and D. Metcalf for valuable discussions; the medical, nursing, and data management staff of the Clinical Oncology and Hematology Units of the participating hospitals, including D. Watson, G. Duggan, S. Oakes, A. Fennessy, A. Woollet, S. Treloar, J. McGrath, and L. Kelsey, for assistance with patient management; K. Alton, M. Vincent, M. Stewart, P. Lockbaum, and J. Marty for assistance and advice; P. Chambers, T. Helton, Y. Hill, L. Hughes, and V. Snelling of Amgen and the staff of Biomedicus (Boronia, Victoria, Australia) for assistance with data verification; and P. Collier and L. Blundy for secretarial assistance.
Grant Support: By Amgen, Inc., and a John Maynard Hedstrom Research Fellowship of the Anti-cancer Council of Victoria.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  J. M. Shammo and F. M. Stewart Hematopoietic growth factors ASH Self-Assessment Program, January 1, 2007; 2007(1): 45 - 60. [Full Text] [PDF]
|
|
|
|
 |
|
 O. A.C. Clark, G. H. Lyman, A. A. Castro, L. G.O. Clark, and B. Djulbegovic Colony-Stimulating Factors for Chemotherapy-Induced Febrile Neutropenia: A Meta-Analysis of Randomized Controlled Trials J. Clin. Oncol., June 20, 2005; 23(18): 4198 - 4214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. L Stanford, S. D Zondor, and E. Cobos Is pegfilgrastim appropriate for the treatment of established febrile neutropenia? Journal of Oncology Pharmacy Practice, June 1, 2003; 9(2-3): 113 - 119. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Garcia-Carbonero, J. I. Mayordomo, M. V. Tornamira, M. Lopez-Brea, A. Rueda, V. Guillem, A. Arcediano, A. Yubero, F. Ribera, C. Gomez, et al. Granulocyte Colony-Stimulating Factor in the Treatment of High-Risk Febrile Neutropenia: a Multicenter Randomized Trial J Natl Cancer Inst, January 3, 2001; 93(1): 31 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ozer, J. O. Armitage, C. L. Bennett, J. Crawford, G. D. Demetri, P. A. Pizzo, C. A. Schiffer, T. J. Smith, G. Somlo, J. C. Wade, et al. 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines J. Clin. Oncol., October 20, 2000; 18(20): 3558 - 3585. [Full Text] [PDF]
|
|
|
|
|
|
C. L. Bennett, J. A. Weeks, M. R. Somerfield, J. Feinglass, and T. J. Smith Use of Hematopoietic Colony-Stimulating Factors: Comparison of the 1994 and 1997 American Society of Clinical Oncology Surveys Regarding ASCO Clinical Practice Guidelines J. Clin. Oncol., November 1, 1999; 17(11): 3676 - 3681. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. H. Kollef The Prevention of Ventilator-Associated Pneumonia N. Engl. J. Med., February 25, 1999; 340(8): 627 - 634. [Full Text] [PDF]
|
|
|
|
|
|
L. C. Hartmann, L. K. Tschetter, T. M. Habermann, L. P. Ebbert, P. S. Johnson, J. A. Mailliard, R. Levitt, V. J. Suman, T. E. Witzig, H.S. Wieand, et al. Granulocyte Colony-Stimulating Factor in Severe Chemotherapy-Induced Afebrile Neutropenia N. Engl. J. Med., June 19, 1997; 336(25): 1776 - 1780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Harker, U. M. Marzec, A. B. Kelly, E. Cheung, A. Tomer, J. L. Nichol, S. R. Hanson, and R. B. Stead Prevention of Thrombocytopenia and Neutropenia in a Nonhuman Primate Model of Marrow Suppressive Chemotherapy by Combining Pegylated Recombinant Human Megakaryocyte Growth and Development Factor and Recombinant Human Granulocyte Colony-Stimulating Factor Blood, January 1, 1997; 89(1): 155 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 ARE GROWTH FACTORS WORTHWHILE FOR FEBRILE NEUTROPENIA? Journal Watch (General), October 14, 1994; 1994(1014): 4 - 4. [Full Text]
|
|
Article
